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Summary
Mutations in the FBN1 gene cause Marfan syndrome
(MFS), a dominantly inherited connective tissue disease.
Almost all the identified FBN1mutations have been fam-
ily specific, and the rate of new mutations is high. We
report here a de novo FBN1mutation that was identified
in two sisters with MFS born to clinically unaffected
parents. The paternity andmaternity were unequivocally
confirmed by genotyping. Although one of the parents
had to be an obligatory carrier for the mutation, we
could not detect the mutation in the leukocyte DNA of
either parent. To identify which parent was a mosaic for
the mutation we analyzed several tissues from both par-
ents, with a quantitative and sensitive solid-phase mini-
sequencing method. The mutation was not, however,
detectable in any of the analyzed tissues. Although the
mutation could not be identified in a sperm sample from
the father or in samples of multiple tissue from the
mother, we concluded that the mother was the likely
mosaic parent and that the mutation must have occurred
during the early development of her germ-line cells. Mo-
saicism confined to germ-line cells has rarely been re-
ported, and this report of mosaicism for the FBN1 mu-
tation in MFS represents an important case, in light of
the evaluation of the recurrence risk in genetic counsel-
ing of families with MFS.
Introduction
Marfan syndrome (MFS; MIM 154700) is a connective
tissue disorder, which in classic form affects ocular, car-
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diovascular, and skeletal systems. The diagnosis of MFS
is given on the basis of clinical and genetic criteria pro-
posed by an international expert committee (De Paepe
et al. 1996). The pleiotropic manifestations are the result
of a defect in fibrillin-1, a major component of elastic
fiber microfibrils in the connective tissue (Sakai et al.
1986). Fibrillin-1 is encoded by the FBN1 gene, located
on chromosome 15q21.1 (Magenis et al. 1991). MFS is
inherited autosomal dominantly, and the majority of the
1130 FBN1mutations reported have been family specific
(Collod-Be´roud et al. 1998). The prevalence of MFS is
∼1:5,000, and the rate of new mutations is quite high
because ∼25% of patients with MFS carry de novo mu-
tations (Pyeritz 1993).
The disease phenotypes caused by FBN1 mutations
range from mild skeletal affection to a lethal neonatal
form of the disease (Kainulainen et al. 1994; Milewicz
et al. 1995).The phenotype also is highly variable among
family members carrying the same FBN1 mutation. In
several other dominantly inherited connective tissue dis-
eases, such as osteogenesis imperfecta or Ehlers-Danlos
syndrome, variable phenotypes have been shown, in
some families, to be caused either by somatic or both
somatic and germ-line mosaicism for the disease-causing
mutation (Cohn et al. 1990; Edwards et al. 1992; Mi-
lewicz et al. 1993). Usually, the mosaic parent has been
clinically normal or has had only minor manifestations,
and the mosaicism is not revealed until the unexpected
recurrence of the disease in the family. Recently, two
cases of mosaicism have been reported in congenital con-
tractural arachnodactyly (CCA), anMFS-like connective
tissue disorder caused by mutations in the fibrillin-2 gene
in chromosome 5 (Wang et al. 1996; Putnam et al. 1997).
The first report described a mosaic mother with classic
CCAwho had a daughter with severe, lethal CCA (Wang
et al. 1996). In the latter case, the proband’s father was
a somatic mosaic for the mutation but had no features
of CCA (Putnam et al. 1997).
It is a little surprising, considering the number of de
novo FBN1 mutations verified, that no cases of germ-
line mosaicism have been reported with MFS. One ex-
ample of an apparently mosaic patient with MFS, a
young girl who had Marfanoid features only in the left
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Table 1
Clinical Features of the Family Members, According to the Diagnostic Criteria for MFS
Feature/Finding Patient 1 Patient 2 Mother Father
Age (years) 9 6.4 37 36
Height (cm/SD) 149.8/2.9 131.4/2.2 161.5/.8 182.0/.8
Span/height 1.02 1 1 1.02
Sitting height (%) 50 51.6 51.5 51.4
Skeletal system:
Mild pectus excavatum    
Wrist and thumb sign    
Pes planus    
Joint hypermobility    
Highly arched palate    
Ocular system:
Ectopia lentisa    
Myopia    
Cardiovascular system:
Dilatation of ascending aortaa    
Mitral valve prolapse    
Family/genetic history:
Affected 1st-degree relativea    
FBN1 mutationa    
NOTE.—Table modified from the report by de Paepe et al. (1996). A plus sign () denotes
feature present; A minus sign () denotes feature absent.
a Major criteria for MFS.
side of her body, has been described by Burgio et al.
(1988). The mutation of the patient has not been re-
ported, but immunofluorescence analysis with a fibrillin
1–specific antibody showed clearly reduced staining of
microfibrillar fibers in the fibroblast cultures from the
affected side of the body versus only somewhat dimin-
ished staining on the “unaffected” side (Godfrey et al.
1990). Another possible example of somatic and germ-
line mosaicism for an FBN1mutation, although not dis-
cussed by Hewett et al. (1994) in their report, may be
the case of a mother with asymmetrical features ofMFS.
She had a daughter who was affected with a severe phe-
notype actually suggestive of Shprintzen-Goldberg syn-
drome (Sood et al. 1996). Because the daughter had died
in 1963, the clinical information was not sufficient to
confirm the diagnosis. This same FBN1 mutation was
described later in a patient with clinically evident
Shprintzen-Goldberg syndrome (Sood et al. 1996), a syn-
drome of craniosynostosis with neurodevelopmental ab-
normalities and features of MFS (Shprintzen and
Goldberg 1982). Finally, a report has just been published
that describes a de novo FBN1 mutation in a patient
with classic MFS and in the patient’s mother, who was
only mildly affected and proved to be a somatic mosaic
for the mutation (Montgomery et al. 1998).
Here we report the same missense mutation in the
FBN1 gene in two sisters with classic MFS who were
born to clinically unaffected parents. The origin of the
mutation was studied by analysis of DNA derived from
different tissue samples of the parents, with a quanti-
tative solid-phase minisequencing method (Syva¨nen et
al. 1993). The analysis suggests that themutational event
must have occurred in the mother’s germ line during her
early fetal development.
Subjects and Methods
Clinical Summary
Patient 1 is a 9-year-old girl who was referred for
diagnostic evaluation at the age of 5 years 9 mo. Physical
examination showed features typical for MFS including
myopia, dolichostenomelia, high arched palate, mus-
cular hypotonia, and joint hypermobility. Cardiac ultra-
sound showed dilatation of the ascending aorta at the
level of the sinus of Valsalva (25–26 mm, 3.0 SD) and
a mitral valve prolapse. Ophthalmologic examination
showed bilateral lens dislocation. She fulfilled the di-
agnostic criteria for MFS (De Paepe et al. 1996). Patient
2 is the sister of patient 1 and is aged 6 years 5 mo. She
was evaluated for MFS first at age 4 years because of
her sister’s diagnosis. Careful clinical examination con-
firmed the diagnosis of MFS. Lens dislocation was bi-
lateral, and aortic dilatation of 2.0 SD at the level of
the sinus of Valsalva was present. The relevant findings
of MFS of the two patients are presented in table 1. The
family history was negative for MFS. Careful clinical
examination, including ophthalmologic evaluation and
cardiac ultrasound study of the parents, did not show
any signs suggestive of MFS (table 1). The mother had
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Figure 1 A, Pedigree of the family with a mosaic mutation. The haplotypes formed by microsatellite markers are shown. Mts-2, -3, and
-4 are multiallelic intragenic FBN1 polymorphisms, and CYP19 is a multiallelic polymorphism located in the immediate vicinity of FBN1
(Pereira et al. 1994; Rantama¨ki et al. 1994). “nd” denotes not determined. Blackened symbols denote affected individuals. The diamond-shaped
symbol denotes a fetus. B, Nucleotide and amino acid sequence of exon 29 in the region of the mutation 3599ArG. Genomic DNA was
sequenced from the father (I-1), mother (I-2), patient 1 (II-1), patient 2 (II-2), and the fetus (II-3). The heterozygous mutation is seen only in
the patients’ samples.
her third pregnancy during the present studies. The ped-
igree of the family is shown in figure 1A.
Samples
Peripheral blood samples were collected from the
mother, father, and patient 2. Skin biopsies were ob-
tained from the mother, father, and patient 1. One sperm
sample was obtained from the father, and buccal, hair
root, and ovarian samples were obtained from the
mother. The buccal samples were obtained by scraping
the mucosa of both cheeks with a cotton swab. Ten hairs
with an intact root, plucked from the head, were used
per each DNA extraction. The paraffin-embedded ovar-
ian sample of the mother had been taken during an op-
eration for endometriosis prior to the conception of her
first child, patient 1. Chorionic villus sampling of the
mother was performed during week 11 of gestation of
her third pregnancy under ultrasound guidance. All the
samples were taken according to the Helsinki
Declaration.
DNA and RNA Extraction
DNA was extracted from peripheral blood leukocytes
and the chorionic villus sample (CVS) by standard meth-
ods (Sambrook et al. 1989). We extracted DNA from
the buccal cells, hair root cells, and semen using the
Chelex-resin procedure (Walsh et al. 1991), and 5–20
ml of the supernatant was used per PCR amplification.
From the paraffin block of ovarian tissue, several pieces
were removed with a scalpel, and DNA was extracted
separately from each tissue piece with the method de-
scribed by Shibata et al. (1988). Ten microliters of the
lysate was used per PCR amplification.
Fibroblast cultures derived from the skin biopsy spec-
imens were grown in Dulbecco’s minimal essential me-
dium (Gibco BRL, Life Technologies) containing 10%
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Figure 2 Schematic representation of the minisequencing strategy and location of the PCR and minisequencing primers. A and A-bio
were used in the first PCR, B and B-bio in the nested PCR, and MS in the minisequencing assay. The nucleotide numbers defining the positions
of the primers in the introns are given. “Bio” denotes a biotin residue.
FCS (Gibco BRL) and antibiotics. DNA was extracted
from confluent cells in a 260-ml flask (Nunc), at the
third to fifth passage of cell culture, by standardmethods
(Sambrook et al. 1989). We extracted total RNA from
the fibroblast cultures, using the guanidinium isothio-
cyanate/cesium–chloride method (Chirgwin et al. 1979).
SSCP Analysis and Sequencing
We prepared cDNA from the total RNA by using re-
verse transcription with FBN1-specific primers. A set of
17 PCR primer pairs was used to amplify the complete
FBN1 cDNA in overlapping fragments, and the frag-
ments were analyzed by SSCP as described by Kainu-
lainen et al. (1992, 1994). A PCR product obtained by
use of the primers flanking exons 29–34 (2a and 2b in
Kainulainen et al. 1992) that produced a shift in SSCP
was sequenced by use of the solid-phase sequencing
method (Syva¨nen et al. 1989).
PCR
Twenty nanograms of genomic DNA was amplified
in a 50-ml reaction, with one biotinylated primer at a
concentration of 0.2 mM, one unbiotinylated primer at
a 1 mM concentration, 0.2 mM of dNTPs, and 1 U
Dynazyme DNA polymerase in its buffer. The primers
were located in the introns flanking exon 29 and had
the following sequences: primer A, 5′-CAGACATCCA-
AACCATATCAG-3′ (nucleotide position 49 to 29),
and primer A-bio, 5′-AACCTACTGAGAGATTCAAC-
AT-3′ (5′-end biotinylated; nucleotide position 41 to
20). For the hair root, buccal, and ovarian lysates, a
nested PCR was done with one primer from the intron
preceding exon 29; primer B, 5′-CATCCAAACCATAT-
CAGAAGGTG-3′ (nucleotide position 45 to 23),
and another, exonic primer, B-bio, 5′-CGGTGCATGA-
TCTCTGGTCAG-3′ (5′-end biotinylated; nucleotides
3712–3692 according to the sequence in Pereira et al.
1993) (fig. 2). One microliter of a 1/100 diluted product
from the first PCR was added to each nested PCR re-
action. PCR was initiated by a hot start at 95C, and
the cycling parameters were 1 min at 95C, 1 min at
57C (primers A and A-bio) or 58C (primers B and B-
bio), and 1 min at 72C, for 30–32 cycles. The quantity
and specificity of the PCR products were assessed by 1%
agarose gel electrophoresis. Control samples without
DNA were included in the first PCR and in the nested
PCRs.
Quantification by Solid-Phase Minisequencing
The relative amount of the alleles in different tissue
samples was measured by use of the solid-phase
mini–sequencing method (Syva¨nen et al. 1993). Ten mi-
croliters of the PCR product was captured in a strep-
tavidin-coated microtiter well (Labsystems). After de-
naturation with 50 mM NaOH, a single-nucleotide-
primer extension reaction was performed for 10 min at
50C with 10 pmol minisequencing primer (5′-
TCATTTCTTTTAGACATTGATG-3′); 0.1 ml of either
3H-dATP, corresponding to the normal allele (81 Ci/
mmol; Amersham), or 3H-dGTP, corresponding to the
mutant allele (31 Ci/mmol; Amersham); and 0.1 U DNA
polymerase (Dynazyme II DNA Polymerase, Finnzymes)
in 50 ml of its buffer. The primer was released with 50
mM NaOH, and the incorporated radioactivity was
measured in a liquid scintillation counter (Rackbeta
1209, Wallac). Two parallel minisequencing reactions
for both nucleotides were done for each PCR product.
Figure 2 illustrates the strategy for the minisequencing
method.
Paternity and Maternity Testing
The paternity and maternity, of the tissue samples, as
well as the identity, were confirmed by genotyping with
the highly polymorphic microsatellite markers
D3S1359, HumTH01, HumTPO, HumFES, HumvWA,
and MCT118. Testing was done in the routine paternity
testing laboratory of the National Public Health Institute
in Helsinki (Budowle et al. 1991; Rostedt et al. 1996).
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Table 2
Series of Minisequencing Standards for Quantification of the
Mutant FBN1 Allele
INCORPORATED
RADIOACTIVITY a
(CPM)
% MUTANT DNA 3H-dGTP 3H-dATP G/A RATIO (RANGE)a
50 (patient 2) 869 2,823 .307 (.299–.314)
25 502 4,708 .107 (.106–.108)
13 288 5,307 .053 (.048–.058)
6.3 175 5,153 .034 (.032–.036)
3.1 136 5,713 .025 (.019–.031)
1.6 86 5,075 .017 (.013–.020)
0.8 66 5,308 .012 (.011–.013)
0 (Control) 84 7,302 .012 (.011–.012)
PCR-H2O 25 27 )
a Mean values and variation range of duplicate minisequencing
assays from the same PCR product.
Genotyping with Intragenic FBN1 Markers
Three multiallelic intragenic FBN1 polymorphisms,
mts-2, mts-3, and mts-4, and a multiallelic polymor-
phism in the vicinity of the FBN1 gene, CYP19, were
used to determine the FBN1 haplotypes in the family
(Pereira et al. 1994; Rantama¨ki et al. 1994).
Results
Identification of the FBN1 Mutation
cDNA derived from the fibroblasts of patient 1 was
screened for FBN1 mutations by SSCP analysis. On the
basis of a shift in SSCP, the respective fragment was
sequenced, and a nucleotide change of ArG was iden-
tified at position 3599 in exon 29 of the FBN1 cDNA
(3599ArG). The corresponding amino acid change is
glycine for a glutamic acid at position 1200 of the fi-
brillin-1 polypeptide (E1200G). The mutation was con-
firmed by sequencing genomic fibroblast DNA with in-
tronic primers flanking exon 29 (fig. 1B). Sequence
analysis of genomic DNA extracted from peripheral leu-
kocytes of the patient’s younger sister (patient 2) showed
the same mutation. However, when the leukocyte DNA
from both the unaffected parents was sequenced, only
the normal allele (A) was identified at position 3599 (fig.
1B). The paternity and maternity were unequivocally
confirmed by use of six highly informative polymorphic
microsatellite markers, by power of evidence values of
99.98% for both sisters (Budowle et al. 1991; Rostedt
et al. 1996). The 3599ArG mutation was not identified
in DNA samples from 40 unrelated patients with MFS
nor from a pool of DNA from 90 control individuals
(Syva¨nen et al. 1993).
To determine the phase of inheritance of the FBN1
alleles, the intragenic FBN1 markers, mts-2, mts-3, and
mts-4, in addition to CYP19, a highly polymorphic
marker in the vicinity of the FBN1 gene, were used to
define the haplotypes in genomic DNA samples (Pereira
et al. 1994; Rantama¨ki et al. 1994). The haplotypes
formed by these four markers indicate that the patients
had inherited the same FBN1 allele from their father
and the same FBN1 allele from their mother. Thus, the
parental origin of the mutation was not obvious (fig.
1A).
The Origin of the Mutation
DNA extracted from the leukocytes and fibroblasts of
both parents, from the sperm of the father and from hair
root and buccal cell samples of the mother, were further
analyzed to define the origin of the FBN1 mutation. In
addition, a paraffin block of ovarian tissue from the
mother was available for sampling. The identity of the
tissues was verified by use of the same panel of micro-
satellite markers as that used for parental testing. The
amount of mutant alleles in different tissues was mea-
sured by use of the solid-phase–minisequencingmethod,
which allows the detection of a mutant allele present in
!1% of a sample (Syva¨nen et al. 1992).
The result of the minisequencing assay is expressed as
the ratio between the labeled dNTPs incorporated in the
two reactions detecting the mutant allele (G) and the
normal allele (A). Leukocyte DNA from a control (0%
mutant) and a patient (50% mutant) and mixtures of
the patient and control DNA (0.8%–25% mutant) were
analyzed to construct a standard curve for quantitative
analysis of the mutation in the tissue samples (table 2).
The G/A ratios obtained in the series of quantification
standards show that there is a linear relationship be-
tween the amount of mutant DNA and the G/A ratios
and that ∼1% of mutant FBN1 DNA is detectable when
compared with the G/A ratio of the control sample. The
analysis of the tissue samples is summarized in table 3.
In the heterozygous patient samples, G/A ratios of .3–.4
were obtained, whereas the control samples gave G/A
ratios of .01. As can be seen from the G/A ratios obtained
in the tissue samples from the parents of the patients,
none of the tissue samples analyzed contained a detect-
able amount of mutant allele (table 3). The absence of
the mutant allele in the father’s sperm sample excludes
the presence of mutation in his germ cells. Unfortunately,
the ovarian tissue of the mother was badly damaged,
and no oocytes could be seen by the hematoxylin/eosin
staining. Thus, the DNA extracted from the block ap-
parently represented DNA from ovarian tissue cells and
not the DNA of the germ cells. Our conclusion, on the
basis of the sensitive and quantitative analysis of rep-
resentative tissues from both parents, is that most likely
the mother is a mosaic in her germ line only for the
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Table 3
Quantitative Determination of the Mutant FBN1
Allele in Tissue Samples of the Family Members
Origin of the DNA
and Family Member G/A Ratioa
Leukocytes:
Patient 2 .307  .011
Father .010  .002
Mother .007  .002
Control .012  .001
Fibroblasts:
Patient 1 .462  .084
Father .011  .002
Mother .009  .003
Control .011  .002
Semen:
Father .009  .003
Hair bulb:
Mother .009  .003
Oral epithelium: .007  .001
Mother
Ovarian tissue:
Mother .007  .002
CVS:
Fetus .007  .003
NOTE.—Mutant FBN1 allele determined by use of
solid-phase minisequencing.
a Mean values and SDs of G/A ratios from at least
four parallel minisequencing assays.
mutation and carries the mutation in an unknown frac-
tion of her oocytes.
Prenatal Diagnosis
The mother became pregnant by her new spouse, and
prenatal diagnosis was performed from a CVS obtained
in week 11 of gestation. Genomic DNA extracted from
the CVS was amplified by PCR, and the A3599G mu-
tation was analyzed both by solid-phase sequencing and
minisequencing. The FBN1 haplotypes obtained from
the CVS were determined by use of one extragenic and
three intragenic polymorphic markers. The A3599Gmu-
tation was not identified in the CVS DNA, and, more-
over, the FBN1 haplotype obtained from the CVS was
different from the haplotypes of patients 1 and 2, in-
dicating that the fetus had inherited a different maternal
FBN1 allele from the patients.
Discussion
In the present study we describe the occurrence of the
same FBN1 mutation in two sisters, with classic MFS,
born to healthy parents who proved to be noncarriers
of the mutation, in their leukocyte DNA. Possible ex-
planations for recurrence of the disease in a family could
be nonpenetrance of the disease, recessive or non-Men-
delian inheritance, wrong paternity, or presence of a hot
spot for mutations. Finally, either of the parents may be
a germ-line mosaic for the disease-causing mutation. Be-
cause MFS is dominantly inherited, the penetrance is
considered to be 100%, the majority of patients have
unique mutations, and no hot-spot region for the mu-
tations has been identified, these explanations for the
event could be excluded in our case (Pyeritz 1993). Both
maternity and paternity were unequivocally confirmed;
thus, it seems most likely that one of the parents was
mosaic in the germ line for the identified mutation.
The assumption that the identified nucleotide change
3599ArG is a true MFS-causing mutation is supported
by the location of the resulting amino acid change
E1200G. Fibrillin-1 polypeptide contains several re-
peating domains, of which the calcium-binding epider-
mal growth factor–like domain is the most common.
These domains have a consensus sequence, D/N-x-D/N-
Q/E-xm-D/N-xn-Y/F, that is known to be associated with
calcium binding (Handford et al. 1991). The mutation
E1200G changes the glutamic acid of this consensus se-
quence to glycine. This glutamic acid has been shown
to participate in direct liganding of Ca2 (Handford et
al. 1991). Therefore, its change to glycine evidently re-
sults in reduced affinity for Ca2 and thus destabilizes
this particular domain, resulting in defective fibrillin-1
molecules. At least 10 missense mutations affecting the
calcium-binding consensus sequence of fibrillin-1 have
been described in patients with MFS (Collod-Be´roud et
al. 1998). Interestingly, the mutation E1200G is located
in the so-called neonatal region, encoded by exons
24–32 of FBN1. This name originated from the clus-
tering of mutations causing lethal neonatal MFS to this
region (Kainulainen et al. 1994; Putnam et al. 1996).
All the missense mutations causing a very severe MFS
phenotype have been concentrated in the narrow region
of exons 24–27, and missense mutations found in pa-
tients with classicMFS have been located in exons 28–32
(Rantama¨ki et al. 1997). Therefore, the region encoded
by exons 24–27 seems to be functionally more essential
in the fibrillin-1 polypeptide than the region encoded by
exons 28–32. Consequently, the classic phenotype in our
patients with a missense mutation in exon 29 cannot be
considered as an exceptional finding.
The aims of our study were to determine which parent
had transmitted the E1200G mutation to the two sisters
and whether the parent carried the mutation only in the
germ-line cells or also in somatic cells. The simplest way
to identify the carrier parent would have been via ge-
notyping, but the genotyping with polymorphic FBN1
markers showed only that both patients had inherited a
common maternal and a common paternal allele. If the
mutation had caused a size difference in FBN1 it would
have been useful in carrier detection. Furthermore, we
failed to identify any additional polymorphisms near the
mutation that would have helped to distinguish paternal
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and maternal alleles. In a recent report by Yates et al.
(1997) of apparent isolated maternal germ-line mosai-
cism in tuberous sclerosis, the authors were able to iden-
tify the carrier parent by using a polymorphic restriction-
enzyme–digestion site. Affected siblings were hetero-
zygous for restriction site present/restriction site absent
polymorphism. By restriction digestion of a PCR prod-
uct containing the mutation, it could be demonstrated
that patients had inherited the mutation from their
mother. Unfortunately, there are no such restriction-site
polymorphisms identified in FBN1. The only polymor-
phism near the mutation 3599ArG is mts-3, for which
the patients were homozygous.
Our evidence for the origin of the mutation in the
presented case, however, indicates the likely maternal
origin of the disease mutation. Because there was no
mutant allele detectable in the sperm sample of the fa-
ther, he could be excluded as a carrier of the mutation.
This is supported by the assumption that, in a case of
two/two affected children in a family, the mutation has
to be present in a significant number of germ cells (Zlo-
togora 1998) and would have been detected by our very
sensitive detection method. Detailed analysis of multiple
maternal somatic tissues gave no evidence for somatic
mosaicism. This finding is consistent with the isolated
germ-line mosaicism of the mother. In isolated germ-line
mosaicism, the new mutation occurs during the early
fetal development of an individual, after the segregation
of somatic cell and germ-line progenitors, whereas in a
case of somatic and germ-line mosaicism mutation oc-
curs earlier, before the separation of cell lineages. The
number of cells carrying the mutation is higher the ear-
lier the mutation occurs (Zlotogora 1998). We suggest
that, in our case, the mother is an obligate carrier and
carries the mutation in an unknown fraction of her oo-
cytes. Unfortunately, this conclusion could not be di-
rectly shown because the potential representative of ma-
ternal germ cells, the paraffin block of ovarian tissue,
contained no histologically identifiable oocytes.
The risk for further affected offspring in a case of
germ-line mosaicism is difficult to estimate, because the
number of germ cells carrying the mutation is not
known. This problem was also discussed in our case,
during the prenatal genetic counseling after the mother
became pregnant by her new spouse. If the mutation had
been present in all the primitive germ cells of the mother,
then the subsequent meiotic divisions would have di-
minished the number of oocytes carrying the mutation
to one-half. Since there is the possibility that at least half
the oocytes do not carry the mutation 3599ArG in a
case of a dominant inheritance pattern, the risk for af-
fected offspring would be 50%.
It is difficult to estimate how many of the sporadic
patients with MFS actually represent offspring of a mo-
saic parent, especially if only leukocyte DNA has been
analyzed by nonquantitative conventional methods with
limited detection sensitivity. The degree of mosaicism
may not be apparent in the leukocytes but would become
evident if other tissues were studied. Cases of somatic
and germ-line mosaicism in which the mutation has been
undetectable in leukocyte DNA have been described, in,
for example, the latest report of mosaicism in CCA (Put-
nam et al. 1997). The mutation was identified by re-
striction-site analysis of PCR products in the hair bulbs
and buccal cells of the proband’s father but was not
detectable from the father’s leukocyte DNA.
Although not shown earlier, mosaicism could be a
more common phenomenon in MFS than has been re-
alized so far. Somatic mosaicism may even be one mod-
ifying factor responsible for the phenotypic variability
among unrelated patients with MFS. Most important,
the present demonstration of germ-line mosaicism in
MFS has implications for genetic counseling. The re-
currence risk in the families with “sporadic” patients
should, therefore, be estimated to be higher than the new
mutation rate alone. Whenever a single child is identified
with an FBN1 mutation and more children are desired,
the parents should be tested, and tissues other than leu-
kocytes should be analyzed. Furthermore, prenatal di-
agnosis should be offered.
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